167 related articles for article (PubMed ID: 1448769)
1. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity.
Primrose JN; Davies JA; Prentice CR; Hughes R; Johnston D
Thromb Haemost; 1992 Oct; 68(4):396-9. PubMed ID: 1448769
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
[TBL] [Abstract][Full Text] [Related]
3. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
4. Effects of moderate weight loss on anginal symptoms and indices of coagulation and fibrinolysis in overweight patients with angina pectoris.
Hankey CR; Lean ME; Lowe GD; Rumley A; Woodward M
Eur J Clin Nutr; 2002 Oct; 56(10):1039-45. PubMed ID: 12373626
[TBL] [Abstract][Full Text] [Related]
5. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitor-1 levels in severe and morbid obesity. Effect of weight loss and influence of 4G/5G polymorphism.
Solá E; Vayá A; España F; Castelló R; Ramón LA; Hernández-Mijares A; Vicente V; Estellés A
Thromb Res; 2008; 122(3):320-7. PubMed ID: 18037477
[TBL] [Abstract][Full Text] [Related]
7. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction--the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction.
Scarabin PY; Aillaud MF; Amouyel P; Evans A; Luc G; Ferrières J; Arveiler D; Juhan-Vague I
Thromb Haemost; 1998 Nov; 80(5):749-56. PubMed ID: 9843166
[TBL] [Abstract][Full Text] [Related]
8. Haemostatic risk factors for cardiovascular diseases.
Koenig W
Eur Heart J; 1998 Apr; 19 Suppl C():C39-43. PubMed ID: 9597424
[TBL] [Abstract][Full Text] [Related]
9. A randomised, controlled study of the effects of aerobic exercise and dietary fish on coagulation and fibrinolytic factors in type 2 diabetics.
Dunstan DW; Mori TA; Puddey IB; Beilin LJ; Burke V; Morton AR; Stanton KG
Thromb Haemost; 1999 Mar; 81(3):367-72. PubMed ID: 10102462
[TBL] [Abstract][Full Text] [Related]
10. Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-Dimer levels.
Erem C; Kocak M; Hacihasanoglu A; Yilmaz M; Saglam F; Ersoz HO
Exp Clin Endocrinol Diabetes; 2008 Nov; 116(10):619-24. PubMed ID: 18484067
[TBL] [Abstract][Full Text] [Related]
11. Obesity, haemostasis and the fibrinolytic system.
Mertens I; Van Gaal LF
Obes Rev; 2002 May; 3(2):85-101. PubMed ID: 12120424
[TBL] [Abstract][Full Text] [Related]
12. Visceral fat as a determinant of fibrinolysis and hemostasis.
Mertens I; Van Gaal LF
Semin Vasc Med; 2005 Feb; 5(1):48-55. PubMed ID: 15968580
[TBL] [Abstract][Full Text] [Related]
13. Plasma PAI-1 levels in obese children--effect of weight loss and influence of PAI-1 promoter 4G/5G genotype.
Estellés A; Dalmau J; Falcó C; Berbel O; Castelló R; España F; Aznar J
Thromb Haemost; 2001 Aug; 86(2):647-52. PubMed ID: 11522017
[TBL] [Abstract][Full Text] [Related]
14. Treatment with a GnRH analogue: effects on hemostatic risk factors for thrombo-embolic disease.
Lindoff C; Petersson F; Samsioe G; Astedt B
Int J Fertil Menopausal Stud; 1994; 39(3):133-9. PubMed ID: 7920748
[TBL] [Abstract][Full Text] [Related]
15. Changes in leptin, plasminogen activator factor and oxidative stress in morbidly obese patients following open and laparoscopic Swedish adjustable gastric banding.
Uzun H; Zengin K; Taskin M; Aydin S; Simsek G; Dariyerli N
Obes Surg; 2004 May; 14(5):659-65. PubMed ID: 15186635
[TBL] [Abstract][Full Text] [Related]
16. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
17. Coagulation and fibrinolytic activity in Behçet's disease.
Hampton KK; Chamberlain MA; Menon DK; Davies JA
Thromb Haemost; 1991 Sep; 66(3):292-4. PubMed ID: 1745999
[TBL] [Abstract][Full Text] [Related]
18. Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus.
Ludwig S; Dharmalingam S; Erickson-Nesmith S; Ren S; Zhu F; Ma GM; Zhao R; Fenton JW; Ofosu FA; Velthuis HT; van Mierlo G; Shen GX
Diabetes Res Clin Pract; 2005 Nov; 70(2):110-8. PubMed ID: 16188573
[TBL] [Abstract][Full Text] [Related]
19. Dyslipidemias and fibrinolysis.
Puccetti L; Bruni F; Pasqui AL; Pastorelli M; Bova G; Cercignani M; Palazzuoli A; Auteri A
Ital Heart J; 2002 Oct; 3(10):579-86. PubMed ID: 12478815
[TBL] [Abstract][Full Text] [Related]
20. Weight change and blood coagulability and fibrinolysis in healthy obese women.
Rissanen P; Vahtera E; Krusius T; Uusitupa M; Rissanen A
Int J Obes Relat Metab Disord; 2001 Feb; 25(2):212-8. PubMed ID: 11410822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
